Anders Karlén

451 total citations
9 papers, 379 citations indexed

About

Anders Karlén is a scholar working on Molecular Biology, Organic Chemistry and Infectious Diseases. According to data from OpenAlex, Anders Karlén has authored 9 papers receiving a total of 379 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 4 papers in Organic Chemistry and 2 papers in Infectious Diseases. Recurrent topics in Anders Karlén's work include Chemical Synthesis and Analysis (4 papers), Computational Drug Discovery Methods (2 papers) and Receptor Mechanisms and Signaling (2 papers). Anders Karlén is often cited by papers focused on Chemical Synthesis and Analysis (4 papers), Computational Drug Discovery Methods (2 papers) and Receptor Mechanisms and Signaling (2 papers). Anders Karlén collaborates with scholars based in Sweden, Switzerland and Italy. Anders Karlén's co-authors include Anders Hallberg, Gunnar Lindeberg, Fred Nyberg, Adolf Gogoll, Petra Johannesson, Torsten Unge, Wesley Schaal, Kristina Bäckbro, Johan Hultén and Nicholas M. Bonham and has published in prestigious journals such as Journal of Medicinal Chemistry, European Journal of Biochemistry and Bioorganic & Medicinal Chemistry.

In The Last Decade

Anders Karlén

9 papers receiving 366 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anders Karlén Sweden	8	218	166	62	57	43	9	379
Robert Gomez United States	13	198 0.9×	240 1.4×	28 0.5×	65 1.1×	54 1.3×	21	431
Jason D. Burch Canada	14	426 2.0×	134 0.8×	37 0.6×	96 1.7×	78 1.8×	25	721
Donald S. Middleton United Kingdom	16	443 2.0×	187 1.1×	26 0.4×	73 1.3×	68 1.6×	45	625
Steven Swallow United Kingdom	13	419 1.9×	162 1.0×	17 0.3×	93 1.6×	18 0.4×	19	616
Patrick DeRoy Canada	10	324 1.5×	102 0.6×	17 0.3×	92 1.6×	43 1.0×	12	461
Rolf Güller Switzerland	10	179 0.8×	186 1.1×	69 1.1×	17 0.3×	8 0.2×	11	374
Jacques Bompart France	11	243 1.1×	141 0.8×	51 0.8×	30 0.5×	6 0.1×	25	425
Z Brzozowski Poland	9	348 1.6×	181 1.1×	26 0.4×	35 0.6×	20 0.5×	47	437
Mary Ann M. Fuhry United States	8	260 1.2×	227 1.4×	66 1.1×	57 1.0×	34 0.8×	10	476
Kang Lin China	8	103 0.5×	158 1.0×	21 0.3×	69 1.2×	29 0.7×	8	353

Countries citing papers authored by Anders Karlén

Since Specialization

Citations

This map shows the geographic impact of Anders Karlén's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anders Karlén with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anders Karlén more than expected).

Fields of papers citing papers by Anders Karlén

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anders Karlén. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anders Karlén. The network helps show where Anders Karlén may publish in the future.

Co-authorship network of co-authors of Anders Karlén

This figure shows the co-authorship network connecting the top 25 collaborators of Anders Karlén. A scholar is included among the top collaborators of Anders Karlén based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anders Karlén. Anders Karlén is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Lu, Lu, Shabbir Ahmad, Sha Cao, et al.. (2022). Synthesis and In Vitro Biological Evaluation of Quinolinyl Pyrimidines Targeting Type II NADH-Dehydrogenase (NDH-2). ACS Infectious Diseases. 8(3). 482–498. 10 indexed citations

Lu, Lu, et al.. (2017). 大腸菌I型シグナルペプチダーゼ(LepB)を標的とするオリゴペプチドの設計,合成およびインビトロでの生物学的評価. Bioorganic & Medicinal Chemistry. 25(3). 911. 1 indexed citations

Rosenström, Ulrika, Christian Sköld, Gunnar Lindeberg, et al.. (2006). Design, Synthesis, and Incorporation of a β-Turn Mimetic in Angiotensin II Forming Novel Pseudopeptides with Affinity for AT₁and AT₂Receptors. Journal of Medicinal Chemistry. 49(20). 6133–6137. 34 indexed citations

Afzelius, Lovisa, Ismael Zamora, Collen Masimirembwa, et al.. (2004). Conformer- and Alignment-Independent Model for Predicting Structurally Diverse Competitive CYP2C9 Inhibitors. Journal of Medicinal Chemistry. 47(4). 907–914. 38 indexed citations

Andersson, Hans O., K. Fridborg, Mathias Alterman, et al.. (2003). Optimization of P1–P3 groups in symmetric and asymmetric HIV‐1 protease inhibitors. European Journal of Biochemistry. 270(8). 1746–1758. 34 indexed citations

Johannesson, Petra, Gunnar Lindeberg, Anja Johansson, et al.. (2002). Vinyl Sulfide Cyclized Analogues of Angiotensin II with High Affinity and Full Agonist Activity at the AT₁Receptor. Journal of Medicinal Chemistry. 45(9). 1767–1777. 114 indexed citations

Johannesson, Petra, Gunnar Lindeberg, Weimin Tong, et al.. (1999). Bicyclic Tripeptide Mimetics with Reverse Turn Inducing Properties. Journal of Medicinal Chemistry. 42(4). 601–608. 17 indexed citations

Johannesson, Petra, Gunnar Lindeberg, Weimin Tong, et al.. (1999). Angiotensin II Analogues Encompassing 5,9- and 5,10-Fused Thiazabicycloalkane Tripeptide Mimetics. Journal of Medicinal Chemistry. 42(22). 4524–4537. 13 indexed citations

Bäckbro, Kristina, Torsten Unge, Johan Hultén, et al.. (1997). Unexpected Binding Mode of a Cyclic Sulfamide HIV-1 Protease Inhibitor. Journal of Medicinal Chemistry. 40(6). 898–902. 118 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact